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A B S T R A C TObjective: To describe real-life prescription patterns, health care
resource use, and costs in adults with generalized anxiety disorder
(GAD) initiating antidepressant (AD) treatment in the United King-
dom. Methods: A retrospective longitudinal cohort study using data
from Clinical Research Practice Datalink was conducted. Adults with
incident prescription of an AD (index date) between January 1, 2006,
and June 30, 2010, and with a diagnosis of GAD within the 2 months
preceding or following the index date were included. Patients with a
diagnosis of schizophrenia or bipolar disorder were excluded. Results:
A total of 29,131 patients with GAD were included in the analysis.
Their mean age was 48.5  15.5 years, and two thirds were women.
GAD-licensed ADs (i.e., escitalopram, paroxetine, venlafaxine XR, and
duloxetine) represented only 12.5% of the index AD prescriptions. At
least one anxiolytic was prescribed for 23.5% of the patients. Only
33.2% of the patients continued index AD treatment over the study
period. Discontinuation occurred for 46.0% of the patients, after asee front matter Copyright & 2013, International S
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ndence to: Julien Chollet, Lundbeck SAS, 37-45 Quaimean of 3.7 months of treatment. The health care costs were £338.4
per patient in the 6 months before the index date and £984.6 in the
9 months after the index date. Psychiatric hospitalization (relative risk
¼ 4.18; 95% CI 3.53–4.96; P o 0.001) and duloxetine as index treatment
(relative risk ¼ 1.85; 95% CI 1.30–2.63; P o 0.001) were the main
determinants of increased costs for these patients. Conclusions: The
signiﬁcant rate of AD discontinuation and associated treatment
duration indicate unmet needs among patients with GAD. As
described in American studies, substantial health care costs were
also observed in this study.
Keywords: antidepressant, generalized anxiety disorder, General
Research Practice Database, health care costs, health care resource
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Anxiety disorders comprise a range of conditions including panic
disorder (with and without agoraphobia), post-traumatic stress
disorder, obsessive-compulsive disorder, social phobia, speciﬁc
phobias, acute stress disorder, and generalized anxiety disorder
(GAD). The lifetime and 12-month prevalence of anxiety disorders
in Europe was estimated, respectively, at 13.6% and 6.4% [1]. In
the United States, anxiety disorders are the most common
mental health disorders with a 12-month prevalence of 18%
and a lifetime prevalence reaching 29% of the population [2,3].
Among anxiety disorders, GAD has a high prevalence and a
large underdiagnosis. GAD is a chronic, common anxiety disorder
in which the patient has excessive worry and apprehension with
regard to circumstances. This disorder is characterized by
difﬁcult-to-control feelings of threat, restlessness, irritability,
sleep disturbance, and tension, and symptoms such as palpita-
tions, dry mouth, and sweating [4]. A systematic international
review showed that the prevalence of GAD is 2.6% over 1 year and
6.2% over lifetime [5]. In the United Kingdom, it was recentlyestimated that 4.4% of the population has GAD, and represents
one third of all patients with anxiety disorders [6]. The economic
burden of GAD is substantial. The overall indirect and direct costs
for GAD have been estimated at $2165 to $3607 per patient per
year in Europe [7,8] and direct health care costs at $6472 in the
United States [9].
In the United Kingdom, the National Institute for Health and
Care Excellence (NICE) edited national clinical guidelines for the
management of GAD [10]. Depending on the increasing severity
of the condition, GAD should be managed according to the
following steps: “i) identiﬁcation and assessment; education
about GAD and treatment options; active monitoring; ii) low-
intensity psychological interventions: individual non-facilitated
self-help, individual guided self-help and psychoeducational
groups; iii) choice of a high-intensity psychological intervention
(CBT/applied relaxation) or a drug treatment; and iv) highly
specialist treatment, such as complex drug and/or psychological
treatment regimens; input from multi-agency teams, crisis serv-
ices, day hospitals or inpatient care.” The preference of the
patient should be taken into account at any of these steps. Ifociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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should be considered: support and information, problem solving,
benzodiazepines, sedating antihistamines, self-help. If benzodia-
zepines are needed, they should not usually be used beyond 2 to
4 weeks. In addition, the longest duration of effect has been
shown for the following interventions, in descending order: “i)
psychological therapy (cognitive behavioural therapy – CBT); ii)
pharmacological therapy (selective serotonin reuptake inhibitors,
SSRIs); or iii) self-help” [10].
Multiple randomized, placebo-controlled trials support the
use of SSRIs as ﬁrst-line pharmacotherapy in anxiety disorders,
particularly in GAD [11]. Currently, in the United Kingdom, two
SSRIs (escitalopram and paroxetine) and two serotonin noradre-
nalin reuptake inhibitors (venlafaxine XR and duloxetine) have
marketing authorizations for the treatment of GAD. Despite its
lack of a UK marketing authorization for this indication, and
based on economic models showing higher cost-effectiveness,
NICE recommends sertraline for the treatment of GAD in its
national clinical guideline. This guideline, however, also states
that “it is difﬁcult to draw conclusions on the cost effectiveness of
particular pharmacological interventions for the treatment of
people with GAD based on existing evidence.”
Although some studies describe treatment patterns and
health care costs of patients with GAD in the United States, we
were unable to identify studies describing the real-life prescrip-
tion patterns of antidepressant (AD) treatment in GAD using a
large European longitudinal medical records database [9,12]. The
Clinical Practice Research Datalink (CPRD, formerly known as the
General Practice Research Database [GPRD]) is an important
source of information for investigating the “real-life” patterns of
use of prescription drugs and health care resource use in primary
care patients in the United Kingdom. Analysis of its data on
patients with GAD could help to choose the appropriate hypoth-
eses to use in models to determine the most cost-effective ADs in
the treatment of GAD. The present exploratory study aimed at
describing the real-life prescription patterns of ADs and associ-
ated health care resource use and costs in adult patients with
GAD recorded in the CPRD.Patients and Methods
Study Design
This study was a retrospective longitudinal cohort study using
data from the GPRD (now known as the CPRD).
Objective
The primary objective of the study was to explore the prescrip-
tion pattern, health care resource use, and costs in adult patients
diagnosed with GAD and initiating an AD treatment in the United
Kingdom.
Study Population
The UK GPRD is the world’s largest computerized database of
anonymous longitudinal clinical records from primary care,
comprising more than 62 million patient-years’ worth of data
collected from approximately 10 million patients since its crea-
tion in 1987 [13]. The data from the GPRD are generated by
general practitioner (GP) practices throughout the United King-
dom, and participating GPs are equipped with speciﬁc software to
record patient data into the database.
Participating clinicians agreed to provide data for research
purposes to the GPRD. Currently, data are being collected from
about 4.8 million patients in 590 primary care practices. These
data cover 8% of the UK population. The patient populationcaptured in the database is broadly representative of the overall
UK population. Prescriptions are directly generated by computer,
thus ensuring a complete recording of prescriptions written by
the GP [14]. Diagnoses were coded by using Read or Oxford
Medical Information System codes and are entered by the GP at
the time of consultation on his own account. The principal
information recorded, and available for analysis, consists of
physician practice characteristics, patient demographics, pre-
scriptions of medicine, clinical diagnoses, referrals to hospitals
or specialists, and results of laboratory tests [13,14]. The external
validity of the GPRD was demonstrated in several studies [15,16].
GAD is frequently comorbid with depression. Because this
study aimed at describing the prescription pattern and resource
use in AD-treated patients with GAD, and not in AD-treated
patients with depression, inclusion and exclusion criteria were
designed to exclude patients with comorbid depression. Patients
in the CPRD corresponding to the following inclusion criteria
were selected: 1) incident prescription of an AD (¼index date); 2)
index date between January 1, 2006, and June 30, 2010; 3) age 18
years or more at the index date; 4) a diagnosis of GAD within the
2 months preceding or following the index date; 5) a minimum of
6 months of history before the index date; 6) a minimum of 9
months of follow-up after the index date; and 7) a second
prescription of AD within the 2 months following the index date.
Exclusion criteria were: 1) any prescription of AD within the 6
months preceding the index date; 2) any diagnosis of depression
within the 3 months preceding or following the index date; 3)
initiation of a combination of AD treatments at the index date;
and 4) diagnosis of schizophrenia or bipolar disorder at any time.
Diagnoses were assessed through a search in Read codes
corresponding to GAD or other psychiatric conditions.
Patient Characteristics
Patient characteristics were described according to the following
sociodemographic and clinical variables extracted from the CPRD
database: age, sex, psychiatric comorbidities during the pre- and
postindex period (GAD, depression, panic disorder, “other anxiety
disorders”—that is, “agoraphobia, speciﬁc phobia and post-
traumatic stress disorders,” obsessive-compulsive disorder, eat-
ing disorders, substance-related disorders) [17]. The Charlson
comorbidity index (CCI) was further calculated according to
adaptation made by Khan et al. [18].
AD Prescription Pattern
Within this study, all marketed antidepressant compounds in the
United Kingdom have been identiﬁed and included, according to
the GPRD Product Dictionary.
AD prescription pattern was described according to 1) type
and duration of index AD treatments; 2) continuation, discontin-
uation, switch, or combination of the index AD treatment; 3)
index AD dose (i.e., proportion of the deﬁned daily dose [DDD]); 4)
medication possession ratio (MPR), deﬁned below; and 5) anxio-
lytic treatment before and after the index date (i.e., benzodiaze-
pines and other anxiolytic drugs according to the GPRD Product
Dictionary).
Duration of the index AD treatment was deﬁned as the period
during which a patient received one or more prescriptions for the
index AD covering a continuous period of time. All AD treatment
changes (e.g., addition of another AD, discontinuation of or
change in AD treatment) were considered as a treatment
sequence change. When two consecutive prescriptions (with
overlaps or not) of the same drug were made within a period of
30 days or less following the theoretical end of the previous
prescription, it was assumed that the patient was treated con-
tinuously. The duration of the index treatment was the difference
Table 1 – Patients’ demographic and clinical
characteristics.
Demographic and clinical characteristics N ¼ 29,131
Age (y), mean  SD 48.5  17.5
Sex: female 19,454 (66.8%)
Calendar year of index date
2006 5,519 (18.9%)
2007 6,584 (22.6%)
2008 6,386 (21.9%)
2009 7,041 (24.2%)
2010 3,600 (12.4%)
Charlson comorbidity index, mean  SD 0.1  0.6
6-mo psychiatric history*
GADs 7,556 (25.9%)
Panic disorder 1,043 (3.6%)
Substance-related disorders 196 (0.7%)
Other anxiety disorders 131 (0.4%)
Eating disorders 47 (0.2%)
OCD 42 (0.1%)
Psychiatric comorbidities†
Depression 1,692 (5.8%)
Panic disorder 1,621 (5.6%)
Other anxiety disorders 354 (1.2%)
OCD 185 (0.6%)
Eating disorders 109 (0.4%)
Substance-related disorders 331 (1.1%)
Note. Unless speciﬁed, results are expressed as n (%).
GADs, generalized anxiety disorders; OCD, obsessive-compulsive
disorder.
 Patients should have no diagnosis of depression during the 3 mo
preceding the index date and no diagnosis of schizophrenia or
bipolar disorder at any time.
† Over the 9 mo following the index date. Patients had a diagnosis
of GAD 2 mo around the index date.
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prescription of the continuous treatment.
The index treatment dose was assessed by using the number
of DDDs. DDDs were obtained from the WHO Collaborating
Centre for Drugs Statistics Methodology, which deﬁnes DDD as
the “assumed average maintenance dose per day for a drug used
for its main indication in adults” [19]. To allow comparison
between drugs, observed doses were divided by the DDD. Doses
are expressed as the prescribed dose divided by the DDD.
AD treatment adherence was estimated by using the MPR [20].
MPR is the sum of the number of days supply of AD prescribed
during the index treatment sequence divided by the total number
of days during that period of time. MPR ranges from 0 (¼no
adherence) to 1 (¼perfect adherence).
Outcomes related to the index AD treatment were classiﬁed as
discontinuation, combination, switch, and continuation. Discon-
tinuing patients were those who had a gap greater than 30 days
between two treatment sequences, no prescription of an anti-
psychotic, and no psychiatric hospitalization during the treat-
ment gap. Switching patients were those who started a new AD
sequence in monotherapy within the 30 days following the end of
a previous treatment sequence. Combining patients were those
who started on a new AD sequence (lasting 430 days or not
followed by another sequence in monotherapy) including more
than one AD within the 30 days following the end of the previous
treatment sequence. Continuing patients were those for whom
no switch, combination, psychiatric hospitalization, or discontin-
uation was recorded during follow-up. In the case of several
successive outcomes, the reported outcome was the ﬁrst to occur
after the index date.
Health Care Resource Use and Health Care Costs
Health care resource use was identiﬁed and computed for the 6
months preceding the index date and for the 9 month following
the index date on the basis of the number of GP visits, GP phone
calls, referrals to psychiatrist/nurse specialized in psychiatry,
other mental health care referrals, psychiatric hospitalizations,
anxiolytics, ADs, and antipsychotics.
Health care costs were calculated on the basis of each unit
cost multiplied by the amount of resources used. Unit costs for
health care resource were extracted from the 2010 version of the
Personal Social Services Research Unit [21]. Because psychiatric
hospitalization duration was not directly available from the GPRD
data, a mean duration was used according to Hospital Episodes
Statistics 2009-2010 [22]. Drug costs were estimated for each
product on the basis of the quantity prescribed and the corre-
sponding package size. Unit costs for drugs were derived from the
British National Formulary [23]. Only the most frequently pre-
scribed formulations were used to calculate a mean cost for each
treatment category. The total cost of health care resource use was
calculated by summing costs for each of the above-mentioned
resource use category over the 9-month observation period and
over the 6-month preindex period.
Statistical Analyses
Descriptive statistics were used to describe patient characteristics
and treatment patterns. Qualitative variables were described by
using frequency and percentage. Quantitative variables were
described by using mean  SD or median (minimum–maximum)
for treatment duration.
Total health care costs were analyzed by using multivariate
generalized linear model regression with log link and gamma
distribution. Regressions were adjusted on the following cova-
riates: 1) patients’ age (in class) and sex, 2) CCI, 3) previous use of
anxiolytics or antipsychotics, 4) previous use of medical resource,5) the calendar year of the index date, and 6) index AD treatment.
Statistical signiﬁcance was set at P r 0.05.
Statistical analyses were performed by using the SAS, version
9, software (SAS Institute, Cary, NC).
The protocol of this study was approved by the GPRD Inde-
pendent Scientiﬁc Advisory Committee for Medicines and Health-
care products Regulatory Agency database research.Results
Patients’ Characteristics
A total of 29,131 patients with GAD with an index prescription of
AD and fulﬁlling inclusion and exclusion criteria were identiﬁed
in the GPRD database between January 1, 2006, and June 30, 2010.
Their mean age was 48.5 17.5 years, and two thirds were
women (Table 1). According to the mean calculated CCI of 0.1,
the incidence of comorbidity was very low for these patients.
Previous psychiatric history over the 6 months preceding the
index date was observed in more than 25% of the patients,
usually relating to a previous diagnosis of GAD (25.9%), panic
disorder (3.6%), and substance-related disorders (0.7%). Psychiat-
ric comorbidities over the 9 months following the index date
were mostly depression (5.8%), panic disorder (5.6%), and “other
anxiety disorders” (1.2%).
Table 2 – Characteristics of the index AD treatment.
Characteristic N ¼ 29,131
Index AD prescription, n (%)
GAD-licensed ADs* 3,655 (12.5)
Unlicensed ADs 25,476 (87.5)
Dose (DDD), mean  SD 0.98  0.63
Duration (d), median (min–max) 139.0 (1.0–274.0)
MPR, mean  SD 0.94  0.08
AD, antidepressant; DDD, deﬁned daily dose; MPR, medication
possession ratio.
 Escitalopram, paroxetine, venlafaxine XR, and duloxetine.
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Fig. 1 – Prescription of anxiolytics before and after the index
date.
46.0
33.2
16.4
4.3
0
10
20
30
40
50
Disconnuaon Connuaon Switch Combinaon
Pe
rc
en
ta
ge
 o
f p
a
en
ts
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 3 3 – 1 1 3 91136AD Treatments
GAD-licensed ADs (i.e., escitalopram, paroxetine, venlafaxine XR,
and duloxetine) represented only 12.5% of the index AD prescrip-
tions (Table 2). The mean  SD daily dose was 0.98  0.63 DDD.
The median duration of treatment was 4.6 months, but very large
differences were observed between patients (i.e., from 1 day to
the whole 9-month observation period). The calculated MPR
value, which was close to 1 in this study, showed a good
estimated adherence to treatment.
At least one prescription of an anxiolytic was observed in
16.6% of the patients before the index date and 23.5% of the
patients during the 9-month observation period. Up to 9% of the
patients had at least three coprescriptions of anxiolytics during
the follow-up (Fig. 1).
Outcomes related to the index AD treatment varied largely
(Fig. 2). Although 33.2% of the patients continued their index AD
treatment, 46.0% discontinued, 16.4% switched, and 4.3% used
the index AD in combination with another AD. On average, an AD
switch was the ﬁrst event to occur (48  50 days) followed by
combination (80  73 days) and discontinuation (112  58 days).48.3
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Fig. 2 – (A) Outcome of the index AD treatment over the
9-month observation period. (B) Mean time (days)  SEM to
modiﬁcation of the index AD treatment. AD, antidepressant;
SEM, standard error of the mean.Health Care Costs
During the 6 months preceding the index date, the mean monthly
health care cost was £56.4 per patient (Table 3). These costs were
mostly for GP visits (£41), psychiatric hospitalization (£10), anti-
psychotics (£2), and GP phone consultations (£2). During the
9-month follow-up, the mean monthly health care cost was £109.4
per patient, mostly corresponding to GP visits (£54), psychiatric
hospitalization (£33), AD (£15), and GP phone consultations (£3).
Multivariate generalized linear model regression analysis was
used to determine the relative risks (RRs) of increased health care
costs during the observation period (Table 4). Increased cost after
the index date was particularly associated with previous psychi-
atric hospitalization (RR ¼ 4.18; 95% CI 3.53–4.96; P o 0.001) and
previous referral to a psychiatrist or a nurse specialized in
psychiatry (RR ¼ 1.66; 95% CI 1.38–2.00; P o 0.001).
Tricyclic antidepressants, “other ADs,” sertraline, venlafaxine
XR, or duloxetine were associated with higher health care costs
than was escitalopram (respective RRs ranging from 1.22 to 1.85;
P o 0.001; see Table 4).Discussion
Close to 30,000 patients with GAD in a large electronic medical
records database in the United Kingdom received an incident AD
treatment between 2006 and 2010. Results showed that 87.5% of
these patients were prescribed an AD that is not licensed in the
United Kingdom for the treatment of GAD. The cost of ADs
represented a small proportion (1/7) of the analyzed health carecosts. Drugs with lower price were not systematically associated
with lower total health care costs.
The proﬁle of patients with GAD is very similar to that of
patients in previous studies, including those observed in a US
database study with 213,589 patients with GAD [9,24]. Patients
with GAD were more frequently women (2:1 sex ratio), were
typically in midlife (48.5  17.5 years), and used anxiolytics
during follow-up (about a quarter). The high level of comorbid
depression or other mental conditions with GAD has been well
documented, and it was estimated that 68% to 93% of GAD
cases could be comorbid with another mental disorder [25,26].
Table 3 – Detailed monthly health care costs (£)
during the 6 mo preceding and 9 mo following the
index date.
Costs (£) 6-mo
preindex
9-mo
postindex
GP visits 40.62 53.74
Psychiatric hospitalizations 10.49 32.63
Antidepressants 0.00 14.95
GP phone calls 2.02 2.57
Antipsychotics 1.57 2.35
Anxiolytics 1.07 1.55
Psychiatrists and psychiatric
nurse referrals
0.59 1.33
Other psychiatric referrals 0.08 0.26
Total 56.44 109.38
GP, general practitioner.
Table 4 – Multivariate generalized linear model
regression.
RR (95% CI) N ¼
29,131
P
Sex: male 1.05 (1.00– 1.10) 0.03
Age (y)
(reference ¼ 18–30 y)
31–49 0.91 (0.86– 0.97) 0.002
50–64 0.89 (0.83– 0.95) 0.001
Z65 1.06 (0.99– 1.14) 0.09
Charlson comorbidity index
(reference ¼ 0)
1 1.10 (0.97– 1.25) 0.14
2 1.16 (1.02– 1.32) 0.02
3 1.20 (0.97– 1.48) 0.09
Medical history
(reference ¼ no use)
Use of anxiolytics 1.24 (1.17– 1.31) o0.001
Use of antipsychotics 1.33 (1.22– 1.45) o0.001
GP visits 1.36 (1.25– 1.48) o0.001
Psychiatric hospitalization 4.18 (3.53– 4.96) o0.001
Other psychiatric referral 1.27 (0.96– 1.69) 0.10
GP phone 1.27 (1.22– 1.34) o0.001
Referral to psychiatrist
or nurse specialized in
psychiatry
1.66 (1.38– 2.00) o0.001
AD treatment
(reference ¼ escitalopram)
Escitalopram 1 –
Paroxetine 1.06 (0.93–1.20) 0.41
Citalopram 1.05 (0.97– 1.13) 0.25
Fluoxetine 1.06 (0.97– 1.16) 0.23
Venlafaxine 1.27 (0.93– 1.75) 0.14
Duloxetine 1.85 (1.30– 2.63) o0.001
Venlafaxine XR 1.49 (1.19– 1.86) o0.001
Sertraline 1.25 (1.11– 1.40) o0.001
TCAs 1.22 (1.11– 1.33) o0.001
Other AD* 1.28 (1.13– 1.44) o0.001
AD, antidepressant; GP, general practitioner; TCAs, tricyclic
antidepressants.
 Other AD class corresponds to all marketed antidepressants in
the United Kingdom excluding those listed. ADs in bold are those
approved for GAD in the United Kingdom.
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seem relatively low in the present study but is due to our decision
to include patients with pure GAD only. As a result, patients with
a diagnosis of schizophrenia or bipolar disorder at any time,
patients with a diagnosis of depression over the 3 months
preceding or following the index date, and patients with any
AD prescription during the preceding 6 months were excluded
from the analysis. This was to avoid possible confusion between
what can be attributed to GAD and what could be due to another
psychiatric condition. In addition, because its primary objective
was to analyze prescription patterns and health care costs
relating to the index AD treatment, only patients with incident
AD prescriptions were included. As a consequence, the results we
obtained relate to AD-treated patients with GAD and to the index
AD treatment.
Whatever the disease, the dose, duration, and adherence of
patients to treatment are essential to achieve success. In this
regard, the pattern of use that we observed is encouraging because
the average duration and adherence of the patient were close to
international recommendations. Because the objectives of the
study were to describe the pattern of use of AD and related health
care costs, patients without an AD prescription were not analyzed.
Analysis of all patients with GD, whatever their treatment, and
also screening studies including nondiagnosed patients, could
provide additional information to better characterize and further
improve the management of patients with GAD.
An important concern as to the management of anxiety
disorders is the prescription of anxiolytics. For many years, these
drugs have been recommended and prescribed for patients with
anxiety disorders, but they are now considered as accessory
treatments in the overall management of anxiety disorders. NICE
“recommends that benzodiazepine should not be offered for the
treatment of GAD in primary or secondary care except as a short-
term measure during crises.” Our results show that a signiﬁcant
proportion of patients (23.5%) received at least one prescription
for an anxiolytic after the index date and up to 9% received at
least three prescriptions for an anxiolytic over the 9-month
observation period. The low number of anxiolytic prescriptions
per patient within this study seems in accordance with current
recommendations and might also indicate that patients were
treated with anxiolytics for a short period of time. Analysis of the
duration of these treatments could be further assessed and
provide additional information as to the proﬁle of anxiolytic
treatment patterns in GAD.
Surprisingly, only 33.2% of the patients continued the index
AD treatment over the entire study period and 46% discontinued
their treatment after an average of 3.7 months. Also, the vastmajority (87.5%) of the prescribed ADs were not licensed in the
United Kingdom for the treatment of GAD. At the time of the
study, ADs licensed for GAD in the United Kingdom were
escitalopram, paroxetine, venlafaxine XR, and duloxetine.
Evaluating health care resource use was an important objec-
tive of this study. Results showed that the health care cost for
patients with GAD treated with antidepressants was substantial,
with a 9-month cost of £984, which corresponds to £1313 per
patient per year. In the perspective of evaluation of burden of
disease and because GAD is largely underdiagnosed (only one
third to half the patients are recognized by GPs), it would be
informative to determine the total health care costs in patients
with GAD treated with treatments other than ADs, including
psychotherapy, as well as in undiagnosed patients with GAD [27].
In addition, GAD is associated with a high impact on daily life
and occupation [11], and underdiagnosis is most likely the cause
of increased costs, especially of indirect costs such as work
productivity (e.g., absenteeism and presenteeism). The present
results show that baseline health care expenditures (£56/month)
are not negligible in patients without AD treatment. These health
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the visits required to diagnose the patient and initiate an
appropriate treatment. The mean cost per GP visit in the United
Kingdom is £35 [21]. Based on the recommendations of four GP
visits over 8 weeks of treatment initiation and 6 months of
maintenance treatment, the total cost for GP visits should be
£140 (GDP expert opinion, NICE recommendations). The expenses
for GP visits were £244 over the 6 months before the index date
and £322 during the 9-month observation period, for a total of
£566. This estimated cost difference can be due to visits for
somatic or psychiatric reasons because it was not possible to
differentiate visits according to diagnosis. The CCI was very low
in included patients (i.e., close to 0), which suggests that visits
were mostly not for severe comorbidities. The hypothesis that a
signiﬁcant part of the GP visits might be related to GAD, however,
is supported by previous results we observed in the United States,
showing that the mean time to the onset of an AD treatment in
patients with GAD was 63 days after the physician had made the
diagnosis [9].
The costs for AD treatments were far from representing the
leading cause of health care cost during the treatment of a GAD
episode. It represented only one seventh of the total health care
costs, far behind GP visits (about half the costs) and psychiatric
hospitalizations (about a quarter). Furthermore, as in any pre-
scription database study, no information was available as to the
delivery of the AD and its use by the patient. In addition, a
comparison performed on two ADs (escitalopram and sertraline)
showed that the higher price of a branded AD was not associated
with higher total health care cost in GAD (£99/month with
escitalopram vs. £134/month with sertraline). This might be
because sertraline treatment initiated at the index date less
frequently prevented worsening of the psychiatric condition.
This would be supported by the twice as high psychiatric
hospitalization costs after the index date in sertraline users
(£56/month) as in escitalopram users (£27/month) (P ¼ 0.001).
Globally, lower health care costs were observed in this study
compared with database analyses performed in the United
States. This is mostly because the study focused on psychiatric
care and GP visits without looking at visits to other specialists, or
hospitalization in nonpsychiatric units. This may also be related
to higher basal health care costs in the United States than in the
United Kingdom.
The CPRD is a very useful tool to perform observational
studies and provides data that cannot be derived from clinical
trials. The main strength of this study resides in the use of the
CPRD database, which allowed extracting and analyzing data
from almost 30,000 patients followed in primary care routine
practice. The CPRD is the largest and most validated medical
records database in Europe and was created in 1987. It allows
long periods of follow-up and observations on patients in a real-
life setting. The accuracy of prescription data contained in this
database is an asset for drug utilization and cost analyses such as
the present study.
The limitations of the present study are similar to those of
many database analyses, and must be known to correctly
interpret the observed data. A major limitation is that no
diagnosis is systematically required and no veriﬁcation of the
diagnoses is performed. This may explain some of the psychiatric
comorbidities reported during the follow-up period, part of which
might correspond to initial misdiagnosis. The analyses are also
subject to the information available in the database, and
unmeasured confounding cannot be ruled out. Another limita-
tion relies in the lack of assurance that the patient actually ﬁlled
in the prescription and used the drug. This is the reason why we
selected patients with at least two AD prescriptions within a
period of time of 2 months. Efﬁciency of this selection criterion is
supported by the good adherence we observed.Conclusions
These European observational data, obtained from more than
29,000 primary care patients, provided useful data, which should
help modeling and determining the most cost-effective strategies
for GAD management. Health care costs were substantial, even
before the index date, and were mostly due to GP visits and
psychiatric hospitalization. Surprisingly, GAD management was
characterized by frequent off-label AD prescriptions. A signiﬁcant
percentage of patients did not receive the recommended duration
of treatment, which highlights the extent of unmet needs in the
care of patients with GAD.Acknowledgment
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